Rallybio expects Avenzo Therapeutics merger to close November 20, 2026
RLYB•Rallybio expects its merger with Avenzo Therapeutics to close after trading on November 20, 2026, subject to remaining closing conditions. The $13.90-per-share special cash distribution is expected to begin November 30, and contingent value rights are expected to be distributed November 23.
1. Merger timeline
Rallybio expects its merger with Avenzo Therapeutics to close following trading on November 20, 2026, subject to remaining closing conditions. Nasdaq cleared Rallybio common stock for listing on the Nasdaq Capital Market in connection with the merger. The $13.90-per-share special cash distribution is expected to begin November 30, unaffected by the planned reverse stock split, and contingent value rights are expected to be distributed November 23, one business day after closing.
Related News
Ligand Pharmaceuticals director Jason Aryeh reports sale of $960,140.98 in common shares
Excelerate Energy executive Alisa Newman Hood sells $240,052.08 in common shares
